C2N, WUSTL Expand Partnership to Commercialize Alzheimer's Test | GenomeWeb

NEW YORK (GenomeWeb) – C2N Diagnostics today announced the expansion of a partnership with Washington University School of Medicine in St. Louis to commercialize a clinical blood test for the detection of Alzheimer's disease at its earliest stages, as well as mild cognitive impairment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.